Dr. Reddy’s completes clinical studies of its rituximab biosimilar for filing in the U.S., Europe

Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions

Merck completes tender offer to acquire Imago BioSciences

Merck intends to complete today the acquisition of Imago through a merger of Merck’s wholly owned subsidiary with and into Imago

Ezharima launched in Japan as first dual EZH1 and EZH2 inhibitor therapy for leukemiaLymphoma

EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years

Merck begins Tender Offer to acquire Imago BioSciences

As a result, Imago will become a subsidiary of Merck.

Jemperli RUBY phase III trial met its primary endpoint

Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival

Merck to acquire Imago BioSciences for $1.35 bn

Acquisition expands Merck’s growing hematology portfolio

Ardigen supports JUMP-CP Consortium scaling up image-based drug discovery with the world’s largest public Cell Painting dataset

The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set

CHMP recommends conditional marketing authorization for Spesolimab for generalized pustular psoriasis flares

CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in

India committed to promote green and climate resilient healthcare facilities: Dr Pawar

Cumulatively, almost 75% of the health centres in the country have been electrified with a cumulative solar capacity of 3.5 MW

CellOrigin Biotech collaborates with Qilu Pharma to develop CAR-iMAC Cell Therapy